Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Reunion Neuroscience logo

About Reunion Neuroscience Stock (NASDAQ:REUN)

Advanced Chart

Key Stats

Today's Range
$1.12
$1.12
50-Day Range
$1.11
$1.13
52-Week Range
$0.63
$5.07
Volume
N/A
Average Volume
210,209 shs
Market Capitalization
$13.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Stock News Headlines

Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

REUN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Reunion Neuroscience investors own include Biora Therapeutics (BIOR), Halliburton (HAL), Meta Platforms (META), Acorda Therapeutics (ACOR), Archer-Daniels-Midland (ADM), Adamis Pharmaceuticals (ADMP) and Applied Genetic Technologies (AGTC).

Company Calendar

Today
5/03/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:REUN
Employees
16
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,690,000.00
Pretax Margin
-2,583.10%

Debt

Sales & Book Value

Annual Sales
$3.88 million
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
0.82

Miscellaneous

Free Float
N/A
Market Cap
$13.13 million
Optionable
Not Optionable
Beta
2.29
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:REUN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners